Young Vulvodynia: Effect and Efficacy of Multimodal Treatment.

The current study is an effectiveness evaluation, applying a sequential single case experimental AB design (SCED) with randomized baseline length, implemented at a youth guidance center. Potential participants will be informed about the study and answer a few questions digitally to ensure that participation in the study is appropriate for them. An assessment will then be conducted and questions will be asked about the pain, psychological, sexual and relational health, and a diagnostic interview will be conducted to exclude other psychological issues that needs to be prioritized before vulvodynia treatment.

After the assessment interview and inclusion, participants will be randomized in tiers to a 4, 5, or 6 week baseline period. Thereafter, the treatment will begin. During the baseline and treatment period, participants will complete a short self-assessment questionnaire, twice a week, to measure pain (primary outcome) and other key variables. To facilitate the repeated assessments, we will use the m-Path app, which was developed by KU Leuven University in Belgium to easily evaluate treatment for both patients and therapists. In addition to the repeated assessments, the treatment will be evaluated through a comprehensive web-based self-assessment questionnaire before and after the intervention and at a six-month follow-up. The outcome measures are in line with Core Outcome set in Vulvodynia.

• Sexual Function [Срок оценки: FSFI: Pre, post treatment (25 weeks after the baseline measurement started) and at 6 month follow-up. FSFI-6 Repeated measures twice a week during baseline (4, 5 or 6 weeks) and treatment period, for 25 weeks.]
• Participant Identified Treatment Goal [Срок оценки: Pre, post treatment (25 weeks after the baseline measurement started) and at 6 month follow-up. Repeated measures twice a week during baseline (4, 5 or 6 weeks) and treatment period, for 25 weeks.]
• Pelvic Floor Tension [Срок оценки: Pre, post treatment (25 weeks after the baseline measurement started) and at a 6 month follow-up. During baseline and treatment period measured twice a week, for 25 weeks.]
• Sexual Satisfaction [Срок оценки: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up]
• Sexual Pain Coping [Срок оценки: Pre, post treatment (25 weeks after the baseline measurement started) and at 6 month follow-up, during baseline (4, 5 or 6 weeks) and treatment period measured twice a week for 25 weeks´.]
• Pain Catastrophizing [Срок оценки: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up]
• Depressive symptoms [Срок оценки: Pre and post treatment, and at 6 months follow-up]
• Anxiety symptoms [Срок оценки: Pre- and post treatment and at 6 month follow-up.]
• Change in quality of life [Срок оценки: Pre and post treatment, and at 6 months follow-up]
• Change in life interference, sexual function interference and communication. [Срок оценки: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up]